BDX Share Price | Becton, Dickinson & Co. Stock Analysis & Recommendation

Q: How big is Becton, Dickinson & Co.?

Market Cap: As of Jun 18, Becton, Dickinson & Co. has a market capitalization of 62,329.13 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Becton, Dickinson & Co. reported net sales of 20,867.00 million and a net profit of 1,519.00 million.Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 25,890.00 million and total assets of 57,286.00 million.

Q: What does Becton, Dickinson & Co. do?

Overview:Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture, and sale of a range of medical supplies, devices, laboratory equipment, and diagnostic products, operating in the Pharmaceuticals & Biotechnology industry with a large-cap market classification.Financial Snapshot:Most recent Net Sales: 5,272 Million (Quarterly Results - Mar 2025)Most recent Net Profit: 308 Million (Quarterly Results - Mar 2025)Market cap: USD 62,329.13 Million (Large Cap)Key Metrics:P/E: 33.00Dividend Yield: 1.89%Debt Equity: 0.73Return on Equity: 7.64%Price to Book: 2.47Contact Details:Address: 1 Becton Dr, FRANKLIN LAKES NJ: 07417-1815Tel: 1 201 8476800Website: http://www.bd.com/

Q: Who are in the management team of Becton, Dickinson & Co.?

As of March 2022, the management team of Becton, Dickinson & Co. includes the following individuals:- Mr. Vincent Forlenza, who serves as the Executive Chairman of the Board.- Mr. Thomas Polen, who holds the positions of President, Chief Executive Officer, Chief Operating Officer, and Director.- Mr. Marshall Larsen, who is the Lead Independent Director.- Ms. Catherine Burzik, who is an Independent Director.- Mr. R. Andrew Eckert, who is also an Independent Director.- Ms. Claire Fraser, who serves as an Independent Director.- Mr. Jeffrey Henderson, who is an Independent Director.In summary, the management team comprises key executives and independent directors, with Mr. Thomas Polen as the CEO and Mr. Vincent Forlenza as the Executive Chairman.

Q: Is Becton, Dickinson & Co. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from very expensive to expensive. This suggests that the company is currently overvalued. Key valuation ratios include a P/E ratio of 33, an EV to EBITDA of 16.57, and a PEG ratio of 2.36, all indicating a premium valuation relative to its peers. For comparison, Abbott Laboratories has a P/E of 18.36 and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, highlighting that Becton, Dickinson & Co. is trading at a higher valuation than these competitors.In terms of recent performance, Becton, Dickinson & Co. has underperformed significantly against the S&P 500, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%. This further reinforces the notion that the stock may be overvalued in the current market environment.

Q: Is Becton, Dickinson & Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and daily moving averages also indicate a bearish trend. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%, and a one-year return of -23.89% versus 19.89% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.56 M

Shareholding (Dec 2025)

FII

23.34%

Held by 525 FIIs

DII

30.21%

Held by 79 DIIs

Promoter

0.01%

How big is Becton, Dickinson & Co.?

22-Jun-2025

As of Jun 18, Becton, Dickinson & Co. has a market capitalization of $62.33 billion, with recent net sales of $20.87 billion and a net profit of $1.52 billion. As of Sep 24, the company reported total assets of $57.29 billion and shareholder's funds of $25.89 billion.

View full answer

What does Becton, Dickinson & Co. do?

22-Jun-2025

Becton, Dickinson and Company (BD) is a global medical technology firm that develops and sells medical supplies, devices, and diagnostic products. As of March 2025, it reported net sales of $5.27 billion and a market cap of approximately $62.33 billion.

View full answer

Who are in the management team of Becton, Dickinson & Co.?

22-Jun-2025

As of March 2022, Becton, Dickinson & Co.'s management team includes Executive Chairman Vincent Forlenza and CEO Thomas Polen, along with several independent directors: Marshall Larsen, Catherine Burzik, R. Andrew Eckert, Claire Fraser, and Jeffrey Henderson.

View full answer

Is Becton, Dickinson & Co. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Becton, Dickinson & Co. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 33 and underperformance of -21.08% year-to-date compared to the S&P 500's 16.30% return.

View full answer

Is Becton, Dickinson & Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Becton, Dickinson & Co. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, and moving averages, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%.

View full answer

Compare Becton, Dickinson & Co. with Similar Stocks

Medtronic Plc Intuitive Surgical, Inc.Stryker Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 5.16% of over the last 5 years

Negative results in Jun 25

With ROCE of 6.24%, it has a expensive valuation with a 1.88 Enterprise value to Capital Employed

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 67,650 Million (Large Cap)

P/E

35.00

Industry P/E

Dividend Yield

2.22%

Debt Equity

0.73

Return on Equity

-3.95%

Price to Book

2.68

Revenue and Profits:

Net Sales:

5,252 Million

(Quarterly Results - Dec 2025)

Net Profit:

382 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.94%

6 Months

-14.71%

1 Year

-8.98%

2 Years

-15.08%

3 Years

-12.36%

4 Years

-18.28%

5 Years

-12.69%

Becton, Dickinson & Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.78%

EBIT Growth (5y)

2.26%

EBIT to Interest (avg)

5.60

Debt to EBITDA (avg)

3.26

Net Debt to Equity (avg)

0.73

Sales to Capital Employed (avg)

0.47

Tax Ratio

11.22%

Dividend Payout Ratio

71.53%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.58%

ROE (avg)

8.05%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.75

EV to EBIT

29.30

EV to EBITDA

16.71

EV to Capital Employed

2.01

EV to Sales

4.14

PEG Ratio

3.86

Dividend Yield

2.14%

ROCE (Latest)

6.87%

ROE (Latest)

7.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 187 Schemes (46.37%)

Foreign Institutions

Held by 525 Foreign Institutions (23.34%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -10.83% vs 6.92% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -22.52% vs -14.11% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,252.00",
          "val2": "5,890.00",
          "chgp": "-10.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,314.00",
          "val2": "1,362.00",
          "chgp": "-3.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "153.00",
          "val2": "155.00",
          "chgp": "-1.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-111.00",
          "val2": "3,124.00",
          "chgp": "-103.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "382.00",
          "val2": "493.00",
          "chgp": "-22.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "133.30%",
          "val2": "149.60%",
          "chgp": "-1.63%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 8.24% vs 4.16% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is -1.58% vs 11.44% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21,840.00",
          "val2": "20,178.00",
          "chgp": "8.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,694.00",
          "val2": "5,231.00",
          "chgp": "8.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "613.00",
          "val2": "528.00",
          "chgp": "16.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "5,005.00",
          "val2": "-676.00",
          "chgp": "840.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,678.00",
          "val2": "1,705.00",
          "chgp": "-1.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "154.80%",
          "val2": "153.00%",
          "chgp": "0.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

5,252.00

5,890.00

-10.83%

Operating Profit (PBDIT) excl Other Income

1,314.00

1,362.00

-3.52%

Interest

153.00

155.00

-1.29%

Exceptional Items

-111.00

3,124.00

-103.55%

Consolidate Net Profit

382.00

493.00

-22.52%

Operating Profit Margin (Excl OI)

133.30%

149.60%

-1.63%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -10.83% vs 6.92% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -22.52% vs -14.11% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

21,840.00

20,178.00

8.24%

Operating Profit (PBDIT) excl Other Income

5,694.00

5,231.00

8.85%

Interest

613.00

528.00

16.10%

Exceptional Items

5,005.00

-676.00

840.38%

Consolidate Net Profit

1,678.00

1,705.00

-1.58%

Operating Profit Margin (Excl OI)

154.80%

153.00%

0.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 8.24% vs 4.16% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is -1.58% vs 11.44% in Sep 2024

All Annual Results

Company CV

About Becton, Dickinson & Co.

Becton, Dickinson & Co.

Pharmaceuticals & Biotechnology

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Company Coordinates

Company Details

1 Becton Dr , FRANKLIN LAKES NJ : 07417-1815

Tel: 1 201 8476800

http://www.bd.com/

Registrar Details